TIGIT [BC41]

T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory domain (TIGIT) is a transmembrane glycoprotein receptor expressed in regulatory and memory T cells, natural killer (NK), and activated T cells (1). As a member of the immunoglobulin superfamily, TIGIT has coinhibitory effects on T-cell dependent immune responses, playing an important role in transplantation tolerance and tumor immune surveillance (2,3). Several studies indicate that TIGIT exhibits synergistic function with the PD-1/PD-L1 pathway in the inhibition of Tcell proliferation. Co-blockade of TIGIT in conjunction with other checkpoint receptors, such as PD-1, has been investigated as a promising immunotherapy in multiple ongoing clinical trials (4).

Specifications

1. Kurtulus S, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest. 2015;125:4053–4062.
2. Johnston RJ, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014;26:923– 937.
3. Zhang Q, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19:723–732.
4. Qin S, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155. 2019 Nov 6.
5. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
6. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014. VP Echelon Series antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare’s antibodies by Ventana Medical Systems, Inc. Biocare and Ventana are not affiliated, associated or related in any way. Ventana®, BenchMark®, ultraView and OptiView are trademarks of Roche.